Get started
89bio, Inc.
Long

$ETNB 89bio Inc Target PTs 29 --> 20 --> 43 and higher

By BADQOMOCAWGOWLD
ETNB 89bio Inc
Target PTs 29 --> 20 --> 43 and higher

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Chart PatternsCypherTechnical Indicators
BADQOMOCAWGOWLD

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.